{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:23:34Z","timestamp":1760315014361,"version":"build-2065373602"},"reference-count":25,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2002,3,28]],"date-time":"2002-03-28T00:00:00Z","timestamp":1017273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2002,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>A Phase II study was performed to investigate the efficacy and tolerability of paclitaxel and ifosfamide chemotherapy for the treatment of anthracycline\u2010resistant metastatic breast carcinoma (MBC).<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Recurrent or progressed MBC within 12 months after anthracycline\u2010based chemotherapy was defined as anthracycline\u2010resistant. A 24\u2010hour infusion of paclitaxel (175 mg\/m<jats:sup>2<\/jats:sup>) on Day 1 and subsequent infusions of ifosfamide (1.8 g\/m<jats:sup>2<\/jats:sup>\/day) with mesna (360 mg\/m<jats:sup>2<\/jats:sup>\/day) on Days 2\u2013 4, were performed every 3 weeks. Twenty\u2010one patients were eligible for toxicity analysis. Response rate and survival duration were evaluated in 21 patients. Frontline chemotherapy was the FAC (5\u2010fluorouracil, doxorubicin, cyclophosphamide) regimen in all patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Objective response was found in 9 patients (42.9%), including complete response in 3 (13.4%). Median response duration and median survival duration were 10 months (range, 2\u201324+) and 19+ months (range, 2\u201332+), respectively. Sixteen (76%) experienced Grade 3\/4 leukopenia controllable with granulocyte macrophage colony\u2010stimulating factor. Other significant toxicities were peripheral neuropathy (<jats:italic>n<\/jats:italic> = 3), mucositis (<jats:italic>n<\/jats:italic> = 2), and liver dysfunction (<jats:italic>n<\/jats:italic> = 1). However, there was no chemotherapy\u2010related death.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Paclitaxel by 24\u2010hour infusion combined with ifosfamide is efficacious in the treatment of anthracycline\u2010resistant MBC with tolerable toxicity. Further trials verifying the result of the authors' study are warranted. Cancer 2002;94:1925\u201330. \u00a9 2002 American Cancer Society.<\/jats:p><jats:p>DOI 10.1002\/cncr.10431<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.10431","type":"journal-article","created":{"date-parts":[[2002,8,25]],"date-time":"2002-08-25T19:46:56Z","timestamp":1030304816000},"page":"1925-1930","source":"Crossref","is-referenced-by-count":7,"title":["A Phase II study of paclitaxel by 24\u2010hour infusion and ifosfamide in anthracycline\u2010resistant metastatic breast carcinoma"],"prefix":"10.1002","volume":"94","author":[{"given":"Jae H.","family":"Seo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young M.","family":"Whang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byung S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chul W.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang W.","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeul H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bum H.","family":"Goo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,3,28]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1988.6.9.1368"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(95)00097-3"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja00738a045"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1021\/np50067a001"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1053\/ctrv.1999.0137"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005882314735"},{"issue":"1","key":"e_1_2_5_8_2","first-page":"28","article-title":"Ifosfamide. European perspective","volume":"9","author":"Burkert H","year":"1982","journal-title":"Semin Oncol"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.5.1152"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.8.2056"},{"issue":"6","key":"e_1_2_5_11_2","first-page":"413","article-title":"Activity of taxol by 3 h infusion in breast cancer patients with clinical resistance to anthracyclines","volume":"29","author":"Munzone E","year":"1993","journal-title":"Eur J Cancer"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.8.1621"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.6.1858"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(97)00260-8"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0305-7372(93)90010-O"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-7372(96)90032-8"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.11.3403"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(97)00217-7"},{"key":"e_1_2_5_19_2","first-page":"629","article-title":"Cisplatinum\u2010taxotere phase I\/II trial in patients with anthracycline\u2010resistant advanced breast cancer","volume":"16","author":"Liombart\u2010Cussac A","year":"1997","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008292332166"},{"issue":"11","key":"e_1_2_5_21_2","first-page":"32","article-title":"Paclitaxel combined with weekly high\u2010dose 5\u2010fluorouracil\/folinic acid and cisplatin in treatment of advanced breast cancer","volume":"23","author":"Klaassen U","year":"1996","journal-title":"Semin Oncol"},{"issue":"12","key":"e_1_2_5_22_2","first-page":"36","article-title":"Activity of ifosfamide in breast cancer","volume":"19","author":"Hortobagyi GN","year":"1992","journal-title":"Semin Oncol"},{"key":"e_1_2_5_23_2","first-page":"56","article-title":"Ifosfamide, methotrexate and 5\u2010FU in advanced pretreated breast cancer","volume":"16","author":"Becher R","year":"1989","journal-title":"Semin Oncol"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199808000-00020"},{"key":"e_1_2_5_25_2","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1177\/030089169808400608","article-title":"Ifosfamide bolus followed by five days continuous infusion in extensively pretreated patients with advanced breast cancer: a phase II study","volume":"84","author":"Bisagni G","year":"1998","journal-title":"Tumori"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980201)82:3<561::AID-CNCR19>3.0.CO;2-#"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.10431","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.10431","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T09:38:38Z","timestamp":1760261918000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.10431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,3,28]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2002,4]]}},"alternative-id":["10.1002\/cncr.10431"],"URL":"https:\/\/doi.org\/10.1002\/cncr.10431","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2002,3,28]]}}}